Philip P. Boudreau - Sep 1, 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Signature
/s/ Philip P. Boudreau, by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Sep 1, 2023
Transactions value $
$0
Form type
4
Date filed
9/6/2023, 06:53 PM
Previous filing
Jun 20, 2023
Next filing
Feb 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +2.62K +16.96% $0.00 18.1K Sep 1, 2023 Direct F1
holding ABT Common shares without par value 349 Sep 1, 2023 Profit Sharing Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +10.2K $0.00 10.2K Sep 1, 2023 Common Shares 10.2K $103.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2023.
F3 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,407 on September 1, 2024, 3,408 on September 1, 2025, and 3,408 on September 1, 2026.